Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

13 May 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer this study is expected to bring an efficient, safe, and convenient first‑line treatment option to patients with advanced cervical cancer
12 May 2026

Alphamab Oncology Announces the First Patient Dosed in Australia Phase I Clinical Study of Subcutaneous TROP2/HER3 Bispecific ADC JSKN016 JSKN016 is designed to address unmet clinical needs, reshaping the ADC treatment experience through formulation innovation
08 May 2026

World Ovarian Cancer Day | Shine Bright, Be the Leading Lady of Life Every medical innovation and clinical advancement breaks the shackles of disease, embodying our commitment to safeguarding patients' love, dignity and hope
30 April 2026

Alphamab Oncology Announces IND Application for TROP2/HER3 Bispecific ADC JSKN016SC Officially Accepted by CDE This application is being reviewed under the "30‑day review channel" for innovative drug clinical trials
23 April 2026

2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer The results guarantee the further development of JSKN016, in combo with chemo, IO and target therapy, in front line and perioperative settings
22 April 2026

2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation This marks a major breakthrough for China-originated innovative therapies on the international academic stage
15 April 2026

National Anti-Cancer Week | Harnessing Innovation to Enable Long-Term, High-Quality Survival for Cancer Patients Technological innovation injects new momentum into cancer treatment
01 April 2026

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint marking a historic breakthrough for bispecific antibodies in the neoadjuvant treatment of breast cancer
26 March 2026

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights Reports Full Year 2025 Financial Results and Business Highlights
24 March 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer The study expected to enroll approximately 1,800 patients with resectable HER2-positive BC